Results 101 to 110 of about 957 (170)

Author Response: Sulbactam-Durlobactam for Carbapenem-resistant <i>Acinetobacter baumannii</i> in India: Does Local Molecular Epidemiology Support Current Guideline Recommendations? and Antibiotic Choice for Carbapenem-resistant <i>Pseudomonas aeruginosa</i>: Need to Look beyond the Forest. [PDF]

Indian J Crit Care Med
Todi SK.
europepmc   +1 more source

A Novel UPLC Method for the Simultaneous Estimation of Sulbactam and Durlobactam in Pharmaceutical Dosage Form

Infectious diseases especially those associated with multidrug-resistant pathogens in critically ill patients are an area of global research and concern for healthcare professionals across both the private and public sectors. Sulbactam and Durlobactam have been approved as a combination drug, called Xacdura, recently for the treatment of hospital ...
openaire   +1 more source

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol : which are the best present and future therapeutic alternatives ?

Purpose: To evaluate the different present and future therapeutic β-lactam/β-lactamase inhibitor (BL/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem ...
Le Terrier, Christophe, Freire, Samanta, Nordmann, Patrice, Poirel, Laurent   +3 more
core   +1 more source

Successful Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infection with Sulbactam-Durlobactam: A Two-Case Report. [PDF]

Infect Drug Resist
Liu F, Wang DW.
europepmc   +1 more source

Synergistic Cefiderocol-Containing Antibiotic Combinations Active Against Highly Drug-Resistant Acinetobacter baumannii Patient Isolates with Diverse Resistance Mechanisms

BACKGROUND: Acinetobacter baumannii is a nosocomial pathogen known for rapidly developing resistance to nearly all antibiotics, including last-line agents. Cefiderocol, a novel siderophore cephalosporin, has shown in vitro activity against A.
Keane, Andrew P, Bouzo, Jeannete, Tran, Jason X, Nolan, Katie T, Halim, Justin, Aderibigbe, Tope, Jonnalagadda, Keertana, Carabetta, Valerie J, Chicola, Jessica A   +8 more
core   +1 more source

A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam. [PDF]

Clin Infect Dis
Sharara SL, Diaz L, Asempa TE, Martinez JRW, Canales N, Bergman Y, Murphy SG, Karaba SM, Clark AE, Zurawski DV, Cosgrove SE, Simner PJ, Munita JM, Tamma PD.   +13 more
europepmc   +1 more source

How to Treat Carbapenem-Resistant Acinetobacter baumannii Infections

: Acinetobacter baumannii, particularly carbapenem-resistant strains (CRAB), represents a critical global health threat due to its multidrug resistance and association with severe healthcare-associated infections.
Cascio, Antonio, Pipito', Luca, Paterson, David L.   +2 more
core   +1 more source

Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii isolates producing OXA-23 or OXA-23 plus PER-1 enzymes. [PDF]

J Antibiot (Tokyo)
Mirza HC, Üsküdar Güçlü A, Ünlü S, Yalçın S.   +3 more
europepmc   +1 more source

Critical Care Management of Pan-Resistant Acinetobacter Osteomyelitis Requiring Novel Antibiotic Therapy

A 65-year-old male with diabetes and chronic left heel osteomyelitis developed sepsis from pan-resistant Acinetobacter baumannii requiring emergent free flap surgery and initiation of sulbactam-durlobactam (Xacduro), a novel, rarely used antibiotic.
Navaratana, Nidhi, Soto, Roy, Thrasher, Patrick D, Shakibai, Nasim   +3 more
core   +1 more source

Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> with Diverse <i>β</i>-Lactamase Profiles: A Multicenter Study in China. [PDF]

Infect Drug Resist
Liu C, Chen Y, Wang L, Wang J, Xu D, Chen Z, Shu C, He Y.   +7 more
europepmc   +1 more source